Elliot Ehrich

Elliot Ehrich has dedicated his career to translating scientific discoveries into new medicines for illnesses that have no effective treatments or are inadequately addressed by existing therapies. Over the course of 25+ years in pharma and biotech, he has led or directly contributed to the discovery, development, and successful registration of 8 medicines across a spectrum of therapeutic areas.

Elliot joined LifeMine from Skyhawk Therapeutics, where he served as President and led the research, drug discovery, and drug development activities. Prior to Skyhawk, Elliot was a Venture Partner at 5 AM Ventures, a venture capital firm focused on early-stage life science companies.

Elliot received a B.A. in Biochemistry from Princeton University. After graduating, he was a predoctoral fellow in molecular genetics at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. He subsequently received an M.D. from Columbia University and completed an internship and residency in internal medicine at Stanford University.